Mizuho Securities Principal Investment logo

Mizuho Securities Principal Investment

Asia, Tokyo, Japan, Tokyo

Description

Mizuho Securities Principal Investment is the investment arm of Mizuho Securities.

Investor Profile

Mizuho Securities Principal Investment has backed more than 3 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 3 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Corporate Round, Series B, Series C rounds (top funding stages).
  • Majority of deals are located in United States, Japan.
  • Strong thematic focus on Medical, Business Information Systems, Document Management.

Stage Focus

  • Corporate Round (33%)
  • Series B (33%)
  • Series C (33%)

Country Focus

  • United States (67%)
  • Japan (33%)

Industry Focus

  • Medical
  • Business Information Systems
  • Document Management
  • Information Services
  • Manufacturing
  • Health Diagnostics
  • Therapeutics
  • Biotechnology
  • Genetics
  • Health Care
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Mizuho Securities Principal Investment frequently co-invest with?

Hamari Chemicals
Asia, Osaka, Japan, Osaka
Co-Investments: 1
Taiwania Capital Management Corporation
Asia, T'ai-pei, Taiwan, Taipei
Co-Investments: 2
Chiyoda Corporation
Asia, Kanagawa, Japan, Yokohama
Co-Investments: 1
Kishida Japan
Asia, Osaka, Japan, Osaka
Co-Investments: 1
Cobro Ventures
North America, Virginia, United States, Arlington
Co-Investments: 2
Co-Investments: 1
RTW Investments
North America, New York, United States, New York
Co-Investments: 2
Axil Capital
Asia, Tokyo, Japan, Tokyo
Co-Investments: 2
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 2
AMED
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1

What are some of recent deals done by Mizuho Securities Principal Investment?

C4 Therapeutics

Cambridge, Massachusetts, United States

C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.

Health DiagnosticsMedicalTherapeutics
Series BJun 16, 2020
Frequency Therapeutics

Lexington, Massachusetts, United States

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue.

BiotechnologyGeneticsHealth CareMedical
Series CJul 23, 2019
PeptiStar

Settsu, Osaka, Japan

PeptiStar continually strives to develop novel manufacturing technologies to address needs in every stage of the peptide value chain.

Business Information SystemsDocument ManagementInformation ServicesManufacturing
Corporate RoundApr 18, 2018
Amount Raised: $186,286,291